Malone-Lee, J and Shaffu, B and Anand, C and Powell, C (2001) Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. The Journal of Urology , 165 (5) 1452 - 1456.
Full text not available from this repository.
PURPOSE: We compared the tolerability and clinical efficacy of tolterodine with those of oxybutynin in patients with an overactive bladder using an upward oxybutynin dose titration strategy analogous to that used in routine clinical practice in the United Kingdom and Republic of Ireland. MATERIALS AND METHODS: In a randomized double- blind trial 378 male and female patients 50 years old or older with symptoms of overactive bladder (a urinary frequency of 8 or more voids per 24 hours with urgency and/or urge incontinence, that is 1 or more urge incontinence episodes per 24 hours) received 10 weeks of treatment with 2 mg. tolterodine twice daily/or an initial dose of 2.5 mg. oxyloutynin twice daily, increasing to 5 mg. twice daily after 2 weeks of treatment. The main outcome measures were changes in voiding diary variables combined with detailed tolerability-safety assessments. RESULTS: Patients treated with tolterodine had significantly fewer adverse events (69% versus 81%, p = 0.01), notably dry mouth (37% versus 61%, p <0.0001), as well as a lower incidence of dose reduction (6% versus 25%, p <0.0001) than those in the oxybutynin group. Each agent had comparable efficacy for improving urinary symptoms. Tolterodine and oxybutynin caused a significant decrease (p = 0.0001) in the mean number of voids per 24 hours (-1.7 or -15% and -1.7 or - 15%, respectively), urge incontinence episodes per 24 hours (-1.3 or - 54% and -1.8 or -62%, respectively) and mean voided volume per void (33 ml. or 22% and 34 ml. or 23%) after 10 weeks of treatment. CONCLUSIONS: Tolterodine is as effective as oxybutynin for improving the symptoms of overactive bladder but it has superior tolerability. The combination of these qualities makes tolterodine the preferred pharmacological therapy for the long-term treatment of this condition
|Title:||Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial|
|Additional information:||UI - 21240851 LA - eng RN - 0 (Benzhydryl Compounds) RN - 0 (Cresols) RN - 0 (Mandelic Acids) RN - 0 (Muscarinic Antagonists) RN - 124937-51-5 (tolterodine) RN - 5633-20-5 (oxybutynin) PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DA - 20010508 IS - 0022-5347 SB - AIM SB - IM CY - United States|
|Keywords:||ACID, Acids, ADVERSE, adverse effects, adverse events, Aged, Aged, 80 and over, AGENT, antagonist, ANTAGONISTS, As, assessment, ASSESSMENTS, Benzhydryl Compounds, bladder, Bladder, Neurogenic, clinical, Clinical practice, Clinical trial, CLINICAL-TRIAL, COMBINATION, Comparative Study, Condition, CONTROLLED TRIAL, Cresols, diaries, dose, DOUBLE BLIND, DOUBLE- BLIND, Double-Blind Method, drug effects, drug therapy, Dry mouth, EFFICACY, EPISODE, EPISODES, EVENTS, Female, FREQUENCIES, FREQUENCY, IM, Incidence, Incontinence, individuals, Ireland, kingdom, LA, LONG-TERM, LONG-TERM TREATMENT, Male, Mandelic Acids, Materials, Methods, MG, Middle Age, Mouth, MULTICENTER, Multicenter Studies, Multicenter Study, muscarinic, Muscarinic Antagonists, NUMBER, old, OLDER, outcome, Outcome measures, overactive bladder, Patient, patients, Pharmacological, practice, QUALITY, randomized, RANDOMIZED CONTROLLED TRIAL, REDUCTION, Result, STATE, STATES, strategies, strategy, Support, Non-U.S.Gov't, SYMPTOM, SYMPTOMS, therapeutic use, THERAPIES, therapy, titration, tolerability, treatment, TRIAL, united, United Kingdom, United States, UNITED-KINGDOM, UNITED-STATES, URINARY, Urination, variable, VARIABLES, VOID, volume|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of) > Clinical Physiology|
Archive Staff Only: edit this record